BTIG raised the firm’s price target on Maze Therapeutics (MAZE) to $37 from $30 and keeps a Buy rating on the shares after the company reported Phase 1 data of MZE782 that the firm said “exceeded expectations and support best-in-class potential.” Based on today’s update, the firm has increased its view of the probability of success for MZE782 to 70% from 55% in PKU and to 65% from 55% in CKD, the analyst noted.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAZE:
- Maze Therapeutics price target raised to $34 from $28 at Leerink
- Kroger reports mixed Q2, U.S. CPI rises 0.4% in August: Morning Buzz
- Maze Therapeutics Secures $150M in Private Placement
- Maze Therapeutics announces results from Phase 1 trial of MZE782
- Maze Therapeutics prices 4M shares at $16.25 in private placement